After flu vaccine hiccups, potential $2.25 billion settlement, where does Moderna go from here?

Moderna agreed to pay $950 million up front and up to $2.25 billion in total to Arbutus and Genevant to settle patent-infringement claims tied to its COVID-19 vaccine, a large potential liability that the company says removes legacy uncertainty; shares rose roughly 7% on the settlement news. The FDA initially refused to review Moderna’s mRNA flu-shot application but reversed course and agreed to review it, while the company is pushing a strategic pivot toward oncology—notably a Phase 3 melanoma vaccine partnered with Merck with results due later this year—which analysts say could offset weakening vaccine revenue as cash burn continues. Investors should weigh the near-term cash/contingent liability hit and regulatory noise against the upside potential from oncology partnerships and international regulatory receptivity.

Analysis

Contrarian angles: The market underestimates non-U.S. commercialization — EU approvals and ex-US demand can offset U.S. regulatory headwinds by 20–40% of vaccine revenue potential; MRNA’s settlement may actually accelerate licensing revenue windows. Consensus may be overpricing permanent U.S. exclusion risk; if the melanoma Phase 3 is positive, the stock rerating could be >50% in 3–12 months. Unintended consequence: large settlements raise the bar for future mRNA entrants and create a small but growing revenue stream for IP holders (benefit to ABUS and other licensors), increasing M&A interest in mid-cap mRNA IP assets.

Key Decisions for Investors

• Establish a 1.5–2.5% long position in ABUS within 5 trading days to capture settlement cash/royalty optionality; target a 25–40% upside over 6–12 months, trim to half at +25% and exit fully at +40% or if cash receipts are delayed >90 days.
• For MRNA, allocate no more than 2% net long via a 6–9 month call spread (bullish only conditional on oncology success): buy a modestly OTM call and sell a higher strike to cap cost; simultaneously buy 3-month 15–25% OTM puts sized at 0.75–1% portfolio to protect against negative FDA/Phase 3 surprises.
• Implement a pair trade: long ABUS (1.5%) / short MRNA (1.5%) initiated on any MRNA rally >10% from current levels; close both positions on the melanoma Phase 3 readout or after 6 months, whichever comes first.
• Rotate 2–3% of biotech exposure away from small-cap infectious-disease vaccine developers into large-cap oncology names (e.g., MRK) within 30 days; this reduces regulatory concentration risk and captures more stable cash flows if U.S. vaccine policy remains hostile.